Diagnosticos da America (BSP:DASA3) Piotroski F-Score: 4 (As of Jun. 27, 2026) — 20% Below Median


BSP:DASA3 Diagnosticos da America SA BSP:DASA3
46 GF Score
Price R$2.78
GF Value R$1.70
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Diagnosticos da America Piotroski F-Score?

Diagnosticos da America BSP:DASA3 -1.42% 46 Piotroski F-Score is 4 as of Jun. 27, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates BSP:DASA3 with a GF Score™ of 46/100 and a GF Value™ of R$1.70 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Diagnosticos da America ranks worse than 51.18% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Diagnosticos da America has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Diagnosticos da America's Piotroski F-Score or its related term are showing as below:

BSP:DASA3' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of Diagnosticos da America was 8. The lowest was 2. And the median was 5.

Diagnosticos da America  (BSP:DASA3) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Diagnosticos da America Piotroski F-Score Related Terms


Diagnosticos da America Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Diagnosticos da America's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diagnosticos da America Piotroski F-Score Chart

Diagnosticos da America Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 3.00 2.00 5.00 4.00

Diagnosticos da America Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 3.00 4.00 4.00 4.00

BSP:DASA3 vs TMO, DHR, IDXX: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Diagnosticos da America's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diagnosticos da America Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diagnosticos da America's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Diagnosticos da America's Piotroski F-Score falls into.


BSP:DASA3
46GF Score
Diagnosticos da America SA BSP:DASA3
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -178.585 + 95.812 + -954.944 + -1.919 = R$-1,040 Mil.
Cash Flow from Operations was -368.976 + 434.129 + 5.624 + -74.071 = R$-3 Mil.
Revenue was 2465.933 + 2608.481 + 2269.676 + 2222.829 = R$9,567 Mil.
Gross Profit was 732.412 + 881.674 + 644.123 + 745.364 = R$3,004 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(28261.545 + 20220.243 + 21098.462 + 18562.235 + 17814.511) / 5 = R$21191.3992 Mil.
Total Assets at the begining of this year (Mar25) was R$28,262 Mil.
Long-Term Debt & Capital Lease Obligation was R$6,446 Mil.
Total Current Assets was R$5,023 Mil.
Total Current Liabilities was R$3,854 Mil.
Net Income was -104.623 + -87.489 + -830.923 + -114.272 = R$-1,137 Mil.

Revenue was 3955.692 + 3969.21 + 3669.185 + 3826.272 = R$15,420 Mil.
Gross Profit was 1139.81 + 1141.817 + 846.133 + 1135.093 = R$4,263 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(26935.2 + 28126.449 + 28290.129 + 26458.471 + 28261.545) / 5 = R$27614.3588 Mil.
Total Assets at the begining of last year (Mar24) was R$26,935 Mil.
Long-Term Debt & Capital Lease Obligation was R$13,585 Mil.
Total Current Assets was R$10,396 Mil.
Total Current Liabilities was R$5,421 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Diagnosticos da America's current Net Income (TTM) was -1,040. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Diagnosticos da America's current Cash Flow from Operations (TTM) was -3. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-1039.636/28261.545
=-0.03678624

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-1137.307/26935.2
=-0.04222382

Diagnosticos da America's return on assets of this year was -0.03678624. Diagnosticos da America's return on assets of last year was -0.04222382. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Diagnosticos da America's current Net Income (TTM) was -1,040. Diagnosticos da America's current Cash Flow from Operations (TTM) was -3. ==> -3 > -1,040 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=6446.062/21191.3992
=0.30418293

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=13584.995/27614.3588
=0.49195403

Diagnosticos da America's gearing of this year was 0.30418293. Diagnosticos da America's gearing of last year was 0.49195403. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=5023.042/3853.593
=1.30346977

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=10395.713/5420.759
=1.91775967

Diagnosticos da America's current ratio of this year was 1.30346977. Diagnosticos da America's current ratio of last year was 1.91775967. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Diagnosticos da America's number of shares in issue this year was 1293.83. Diagnosticos da America's number of shares in issue last year was 1288.468. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=3003.573/9566.919
=0.31395405

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4262.853/15420.359
=0.27644317

Diagnosticos da America's gross margin of this year was 0.31395405. Diagnosticos da America's gross margin of last year was 0.27644317. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=9566.919/28261.545
=0.33851366

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=15420.359/26935.2
=0.5724984

Diagnosticos da America's asset turnover of this year was 0.33851366. Diagnosticos da America's asset turnover of last year was 0.5724984. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+1+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Diagnosticos da America has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Diagnosticos da America (BSP:DASA3) has a Piotroski F-Score of 4 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Diagnosticos da America and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, Diagnosticos da America's Piotroski F-Score has ranged from 2.00 to 8.00. According to the industry distribution chart, Diagnosticos da America ranks #108 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 51.2%.
Is Diagnosticos da America's Piotroski F-Score too high?
Diagnosticos da America's current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Diagnosticos da America's value of 4 is 20% below this industry median. Based on the distribution chart, Diagnosticos da America ranks #108 out of 211 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Diagnosticos da America has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnosticos da America's Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diagnosticos da America ranks #108 out of 211 companies for Piotroski F-Score. This places Diagnosticos da America in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Diagnosticos da America's value of 4 is 20% below this benchmark. Historically, Diagnosticos da America's own Piotroski F-Score has ranged from 2.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Diagnosticos da America has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diagnosticos da America's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Diagnosticos da America and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnosticos da America's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnosticos da America stock overvalued right now?
Based on GuruFocus' analysis, Diagnosticos da America (BSP:DASA3) is currently considered Significantly Overvalued. The stock's GF Value™ is R$1.70, compared to a current price of R$2.78 — trading 63.5% above its estimated fair value. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Medical Diagnostics & Research industry median of 5.00. Diagnosticos da America's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Diagnosticos da America (BSP:DASA3), the current Piotroski F-Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diagnosticos da America (BSP:DASA3) Overvalued in 2026?

Based on GuruFocus' analysis, Diagnosticos da America stock appears to be overvalued. The current stock price of R$2.78 is trading 63.5% above its estimated GF Value™ of R$1.70. GuruFocus considers Diagnosticos da America to be Significantly Overvalued.

Key valuation signals for BSP:DASA3:

  • Piotroski F-Score: 4 (20% below median its 10-year median of 5.00)
  • GF Value™: R$1.70 vs. price of R$2.78 (63.5% above fair value)
  • GF Score™: 46/100 with 3 warning signs
  • Industry Position: 20% below the Medical Diagnostics & Research median (#108 of 211)

No single metric tells the full story. See the BSP:DASA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Diagnosticos da America Business Description

Address Avenida Jurua, 434, Alphaville, Barueri, SP, BRA, 06455-010
Diagnosticos da America SA operates as a medical diagnostics company in Brazil. The company offers clinical analysis, diagnostic imaging tests, and patient service centers. It has three operating segments. Outpatient care services and care coordination includes Diagnosis and health management, Hospitals and oncology include Medical and hospital services & Foreign operations include Diagnosis. The majority is from the Hospitals and oncology segment. Geographically, it operates in Brazil and South America (Argentina, Uruguay, Chile and Colombia).
46GF Score

Get the complete analysis for BSP:DASA3

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$2.78
Price
R$1.70
GF Value